Richard Junior Zapata Dongo

Mr. Richard Junior Zapata Dongo

Medicine school, National University of San Marcos, Lima, Peru
orcid
Ph.D student at National University of San Marcos

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJuan Enrique Faya Castillo
Juan Enrique Faya Castillo
Richard Junior Zapata DongoRichard Junior Zapata Dongo
Richard Junior Zapata Dongo
PCPaolo Alberto Wong Chero
Paolo Alberto Wong Chero
SIStefany Fiorella Infante
Stefany Fiorella Infante
Non-small cell lung cancer (NSCLC) is a type of lung cancer associated with translocation of the EML4 and ALK genes on the short arm of chromosome 2. This leads to the development of an aberrant protein kinase with a deregulated catalytic domain, the cdALK+. Currently, different ALK inhibitors (iALKs) have been proposed to treat ALK+ NSCLC patients. However, the recent resistance to iALKs stimulates the exploration of new iALKs for NSCLC. Here, we describe an in silico approach to finding FDA-approved drugs that can be used by pharmacological repositioning as iALK. We used homology modelling to obtain a structural model of cdALK+ protein and then performed molecular docking and molecular dynamics of the complex cdALK+-iALKs to generate the pharmacophore model. The pharmacophore was used to identify potential iALKs from FDA-approved drugs library by ligand-based virtual screening. Four pharmacophores with different atomistic characteristics were generated, resulting in six drugs that satisfied the proposed atomistic positions and coupled at the ATP-binding site. Mitoxantrone, riboflavin and abacavir exhibit the best interaction energies with 228.29, 165.40 and 133.48 KJoul/mol respectively. In addition, the special literature proposed these drugs for other types of diseases due to pharmacological repositioning. This study proposes FDA-approved drugs with ALK inhibitory characteristics. Moreover, we identified pharmacophores sites that can be tested with other pharmacological libraries.

1 December 2023 in World Journal of Oncology
Verified
Journal Article
Open access
PDF file
RRRenzo Martin Chapilliquen Ramirez
Renzo Martin Chapilliquen Ramirez
MPMariana Teresa de Jesus Corbacho Pachas
Mariana Teresa de Jesus Corbacho Pachas
Richard Junior Zapata DongoRichard Junior Zapata Dongo
Richard Junior Zapata Dongo
Prevalence and Prognosis of Secondary Genetic Aberrations Among Patients With Core Binding Factor Acute Myeloid Leukemia: A Mitelman Database Analysis

6 September 2025 in Veterinary World
Verified
Journal Article
Open access
JRJuan Pedro Rojas-Armas
Juan Pedro Rojas-Armas
JAJorge Luis Arroyo Acevedo
Jorge Luis Arroyo Acevedo
MPMiriam Palomino-Pacheco
Miriam Palomino-Pacheco
JOJosé Manuel Ortiz-Sánchez
José Manuel Ortiz-Sánchez
Hugo Jesús Justil-GuerreroHugo Jesús Justil-Guerrero
Hugo Jesús Justil-Guerrero
Richard Junior Zapata DongoRichard Junior Zapata Dongo
Richard Junior Zapata Dongo
Background and Aim: Coriandrum sativum L. (coriander) has long been valued for its culinary and medicinal uses. C. sativum essential oil (CsEO), particularly linalool-rich chemotypes, exhibits diverse biological activities; however, integrated evalu­ations encompassing neurological, inflammatory, and molecular targets remain limited. This study aimed to chemically characterize Peruvian CsEO and assess its anticonvulsant, analgesic, anti-inflammatory, and antioxidant effects, alongside those of pure linalool, while elucidating potential mechanisms through cytokine modulation and molecular docking of cyclooxygenase (COX) enzymes. Materials and Methods: CsEO was extracted from Peruvian coriander seeds through steam distillation and analyzed using gas chromatography–mass spectrometry (GC-MS). Antioxidant activity was quantified using the 2,2′-azino-bis(3-ethylbenz­thiazoline-6-sulfonic acid) assay. Anticonvulsant effects were tested in BALB/c mice using the pentylenetetrazole-induced seizure model, analgesic activity through the acetic acid-induced writhing test, and anti-inflammatory effects in Holtzman rats using the carrageenan-induced paw edema model. Serum interleukin-1β (IL-1β) and interleukin-6 (IL-6) levels were measured by enzyme-linked immunosorbent assay. Molecular docking evaluated linalool’s binding affinity to COX-1 and COX-2 relative to standard non-steroidal anti-inflammatory drugs. Results: GC-MS identified linalool as the major constituent (59.80%), alongside α-pinene (8.65%), camphor (8.48%), and γ-terpinene (7.09%). CsEO demonstrated potent antioxidant activity (half-maximal inhibitory concentration [IC50] = 32.04 μg/mL), exceeding that of linalool alone (IC50 = 152.29 μg/mL). Significant anticonvulsant effects occurred at 200 mg/kg for both CsEO and linalool, increasing seizure latency by up to 87.20% and reducing seizure frequency by ~43%. In analgesic assays, linalool (200 mg/kg) achieved a 93.80% writhing reduction, comparable to tramadol, while CsEO showed strong but slightly lower efficacy. CsEO (200 mg/kg) inhibited carrageenan-induced edema by 51.35% at 4 h, reduced IL-1β by 49.8%, and IL-6 by 26.5%, effects comparable to ibuprofen. Docking revealed moderate linalool affinity for COX-1 (−5.70 kcal/mol) and COX-2 (−6.10 kcal/mol), sharing key hydrophobic interactions with reference drugs. Conclusion: Peruvian CsEO, characterized by a distinctive linalool-rich chemotype, exhibits significant multi-target pharma­cological activities, with synergistic contributions from minor constituents enhancing antioxidant and anti-inflammatory effects. Its integrated efficacy profile and favorable safety indicators highlight CsEO as a promising phytotherapeutic candi­date for managing seizures, pain, and inflammation. Further studies should explore chronic models, pharmacokinetics, and formulation strategies to optimize clinical applicability. Keywords: analgesic, anticonvulsant, anti-inflammatory, antioxidant, Coriandrum sativum, cytokines, essential oil, linalool, molecular docking.

18 June 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Richard Junior Zapata DongoRichard Junior Zapata Dongo
Richard Junior Zapata Dongo
JPJulio A. Poterico
Julio A. Poterico
DFDiletta Fontana
Diletta Fontana
LMLuca Mologni
Luca Mologni
CACarla Alvarez-Chacon
Carla Alvarez-Chacon
JCJaeson Calla
Jaeson Calla
The anaplastic lymphoma kinase (alk) gene on chromosome 2 encodes a receptor tyrosine kinase protein essential for key signaling pathways regulating cell proliferation and differentiation. Mutations in alk have been implicated in multiple cancers, including non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma. While ALK inhibitors have demonstrated efficacy in targeted therapies, resistance due to specific amino acid substitutions requires the development of novel therapeutic strategies. This study aims to identify ALK tyrosine kinase domain mutations using data from the Cancer Genome Atlas and to evaluate the potential of lorlatinib, a third-generation ALK inhibitor, in overcoming these mutations. Using the SIFT and Polyphen-2 algorithms, we identified 53 deleterious ALK mutations associated with different newly recognized cancer types. These mutations were subjected to in silico molecular docking with lorlatinib. Our results indicate strong binding affinities (ranging from −9.4 to −10.8 kcal/mol) across all identified mutations, suggesting a significant interaction between lorlatinib and mutated ALK variants. Furthermore, protein-ligand interaction analysis revealed critical hydrophobic interactions, hydrogen bonds, and essential halogen bonds reinforcing lorlatinib as a potential utility in treating a broader spectrum of ALK-positive tumors beyond NSCLC. This research underscores the importance of repurposing in silico drugs and highlights the need for continued exploration of ALK mutations in cancer therapeutics.

21 January 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Richard Junior Zapata DongoRichard Junior Zapata Dongo
Richard Junior Zapata Dongo
DFDiletta Fontana
Diletta Fontana
LMLuca Mologni
Luca Mologni
JCJuan Enrique Faya Castillo
Juan Enrique Faya Castillo
SVStefany Fiorella Infante Varillas
Stefany Fiorella Infante Varillas
The anaplastic lymphoma kinase (ALK) oncoprotein plays a crucial role in non-small cell lung cancer (NSCLC) by activating signaling pathways involved in cell proliferation and survival through constitutive phosphorylation. While first-line crizotinib can regulate phosphorylation, mutations in the ALK gene can lead to resistance against ALK inhibitors (ALKi) such as ceritinib and alectinib. On the other hand, overexpression of BCL2, a protein involved in cell death regulation, has been observed in NSCLC and is considered a potential therapeutic target. In this study, we propose to inhibit BCL2 as a secondary therapeutic target in EML4-ALK cell models to overcome resistance caused by ALK mutations. Four Ba/F3 EML4-ALK cell models (WT, C1156Y, L1196M, and G1202R) generated by site-directed mutagenesis exhibited varying levels of BCL2 expression. Both the WT and G1202R models showed overexpression of BCL2, while C1156Y and L1196M models approached baseline levels. We treated these cells with ABT-199, a selective BCL2 inhibitor, and found that models with high BCL2 expression exhibited resistance, while those with lower expression showed sensitivity to BCL2 inhibition. In addition, our analysis using bioinformatics indicated that ABT-199 not only targets BCL2 but also binds to the active site of all ALK mutants, it was contrasted by in vitro ALK kinase activity inhibition by ABT-199 (5.5 μM). This interaction was further supported by a significant decrease of ALK phosphorylation in single and combination treatment with 300nM ABT-199. Finally, when ABT-199 was combined with ALKi, we observed a wide range of synergistic effects in the WT and G1202R cell models, while the C1156Y and L1196M models showed limited synergy. In conclusion, our findings indicate that BCL2 targeting with ABT-199, in combination with ALKi, can significantly reduce tumor cell survival in Ba/F3 EML4-ALK cell models.

1 April 2026 in World Journal of Oncology
Verified
Journal Article
Open access
PDF file
MBMilder Bravo-Davila
Milder Bravo-Davila
DEDayana Espinoza-Rodrigez
Dayana Espinoza-Rodrigez
JOJavier Orejon-Huarancca
Javier Orejon-Huarancca
Richard Junior Zapata DongoRichard Junior Zapata Dongo
Richard Junior Zapata Dongo
Background: Acute myeloid leukemia (AML) with t(16;21) translocation is an infrequent hematological neoplasia. This study aimed to describe the cytogenetic, molecular and immunophenotypic profiles of this disease. Methods: We conducted a descriptive observational study using secondary data. AML cases with the t(16;21) translocation were identified from the Mitelman database and systematic searches in PubMed, Scopus, SciELO and Genetics and Cytogenetics in Oncology and Hematology databases. Cytogenetic, molecular, immunophenotypic and clinical variables were extracted. We performed descriptive and survival statistical analyses at 2 and 5 years. Results: We identified 103 cases with AML with t(16;21). Most cases were t(16;21)(p11;q22) (n = 90, 87.4%), with recurrent additional abnormalities including +10 (14.4%), –16 (7.8%), add(11) (5.6%), and del(6) (4.4%), while t(16;21)(q24;q22) cases mainly showed +8 (45.5%) and del(9) (18.2%). FUS::ERG was reported in 62.2% of t(16;21)(p11;q22) cases, whereas RUNX1::RUNX1T3 was detected in 72.2% of t(16;21)(q24;q22). Immunophenotypically, t(16;21)(p11;q22) cases expressed (among the cases evaluated) cluster of differentiation (CD)13 (100%), CD33 (96.6%), CD34 (98.0%), CD56 (93.0%), and MPO (84.8%), while all evaluated t(16;21)(q24;q22) cases were positive for CD13, CD33, CD34, and MPO. Relapse information was missing for a substantial proportion of cases; among those with available data (65.0%), relapse occurred in 51 cases (76.1%). The 5-year mortality rate was significantly higher in the t(16;21)(p11;q22) group than in the t(16;21)(q24;q22) group (P = 0.012), with no significant difference at 2 years. Conclusions: The cytogenetic, molecular, and immunophenotypic characteristics of AML with t(16;21) vary according to the chromosomal breakpoint. The t(16;21)(p11;q22) translocation was the most frequently reported and was frequently associated with CD56 expression. The findings suggest that patients with t(16;21)(p11;q22) exhibited lower 5-year survival compared with the other group, highlighting the unfavorable outcomes observed in reported cases.